Skip to search formSkip to main contentSkip to account menu

Antiparkinson Agents

Known as: antiparkinsonian drugs, ANTI-PARKINSON DRUGS, Antiparkinson Drugs 
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or… 
National Institutes of Health

Related topics

Related topics

47 relations

Narrower (38)

24 HR Pramipexole dihydrochloride 0.75 MG Extended Release Oral Tablet24 HR Rotigotine 0.0417 MG/HR Transdermal System24 HR Rotigotine 0.25 MG/HR Transdermal SystemApomorphine

Broader (1)

Central Nervous System Depressants
Cholinergic AntagonistsDopamine AgonistsIn BloodParasympatholytics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease
In Parkinson's disease (PD), dyskinesia develops following long‐term treatment with 3,4‐dihydroxyphenylalanine (L‐dopa). Given… 
Highly Cited
2005
Highly Cited
2005
Agonism at 5-HT2B receptors is not a class effect of the ergolines.
Highly Cited
2002
Highly Cited
2002
Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
To study the association between polymorphism of the cytochrome P450 2D6 gene (CYP2D6) and the risk of antipsychotic-induced… 
Review
2000
Review
2000
Hair Loss in Psychopharmacology
Medication-induced alopecia is an occasional side effect of many psychopharmaceuticals. Most of the mood stabilizer and… 
Review
1996
Review
1996
Memory Impairment in Schizophrenia: Perspectives from Psychopathology and Pharmacotherapy
  • E. Stip
  • Canadian journal of psychiatry. Revue canadienne…
  • 1996
  • Corpus ID: 45562534
Objective: To describe the concept of memory impairment in schizophrenia and the clinical implications of this concept in terms… 
Review
1978
Review
1978
Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.
The effects of ergot drugs on central monoaminergic mechanisms, particularly dopaminergic mechanisms, have been investigated in… 
Highly Cited
1974
Highly Cited
1974
The Abrupt Withdrawal of Antiparkinsonian Drugs in Schizophrenic Patients
Phenothiazines and other neuroleptic drugs are known to cause extrapyramidal side-effects. Consequently antiparkinsonian (AP… 
Highly Cited
1973
Highly Cited
1973
Effect of sodium, hemicholinium-3 and antiparkinson drugs on (14C)acetylcholine synthesis and (3H)choline uptake in rat striatal synaptosomes.
Highly Cited
1972
Highly Cited
1972
Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
Chronic schizophrenic males receiving both antipsychotic and antiparkinson medication had the latter replaced by placebo for a… 
Highly Cited
1965
Highly Cited
1965
THE IMPORTANCE OF LIPID-SOLUBILITY FOR THE CENTRAL ACTION OF CHOLINOLYTIC DRUGS.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)